Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials
Rangel-Huerta OD, Aguilera CM, Mesa MD, Gil A
The British journal of nutrition · 170 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Instituto de Salud Carlos III
Según 1 financiador declarado.
Publicación
- Publicado
- 2012-05-17 · Br J Nutr · vol. 107 · número S2 · págs. S159–S170
- Editorial
- Cambridge University Press
- Citado
- 237 citas · más que el 93% de estudios similares · 3.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 57 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Fatty Acid Research and Health · Edible Oils Quality and Analysis · Inflammatory mediators and NSAID effects
- Palabras clave
- omega-3 fatty acids, long-chain polyunsaturated fatty acids, dietary supplementation, inflammatory markers, inflammation, cardiovascular disease, sepsis, acute pancreatitis, chronic kidney disease, endothelial activation, eicosanoids, cytokines, chemokines, adhesion molecules
- MeSH
- endothelium, humans, sepsis, pancreatitis, kidney failure, chronic, cardiovascular diseases, inflammation, fatty acids, omega-3, anti-inflammatory agents, inflammation mediators, dietary supplements, randomized controlled trials as topic, biomarkers
4 autores
- Óscar Daniel Rangel-Huerta🇪🇸Universidad de Granada
- Concepción María Aguilera🇪🇸Universidad de Granada
- María Dolores Mesa🇪🇸Universidad de Granada
- Ángel Gil🇪🇸 · autor de correspondenciaUniversidad de Granada
Resumen
El texto original del estudio, en el idioma en que se publicó.
Inflammation is part of the normal host response to infection and injury. Eicosanoids, cytokines, chemokines, adhesion molecules and other inflammatory molecules are frequently produced during this process. Numerous studies in humans have documented the inflammation-limiting properties of omega-3 fatty acids, but only a few have been randomised clinical trials. The aim of this study was to perform a systematic search of randomised clinical trials on omega-3 fatty acids and inflammatory biomarkers in all subjects including healthy and ill persons up to February 2011 using PubMed and LILACS databases, defined by a specific equation using MeSH terms and limited to randomised clinical trials; there was no any a priori decision to include some diseases and not others. The quality of each publication was validated by using the JADAD scale and the CONSORT checklist. Inflammatory biomarkers were considered as primary outcomes. Twenty-six publications of the last 10 years were selected. Studies included healthy subjects and patients with cardiovascular disease and other chronic and acute diseases; all reported the number of subjects, type of study, type and doses of omega-3 fatty acids, main outcomes and major inflammatory biomarkers. Dietary omega-3 fatty acids are associated with plasma biomarker levels, reflecting lower levels of inflammation and endothelial activation in cardiovascular disease and other chronic and acute diseases, including chronic renal disease, sepsis and acute pancreatitis. However, further research is required before definitive recommendations can be made about the routine use of omega-3 fatty acids in critically ill patients or with neurodegenerative or chronic renal disease.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.